Third-Quarter Revenue Climbs to $493 Million with Adjusted EPS of $2.39
Revenue momentum was driven primarily by rapid expansion across the company's high-margin royalty streams. Third-quarter royalty revenue surged 44 percent year over year to $341.0 million, compared to $236.0 million reported in the corresponding period of 2025. Halozyme's proprietary ENHANZE drug delivery technology—utilizing recombinant human hyaluronidase to temporarily degrade subcutaneous hyaluronan—is licensed by tier-one pharmaceutical developers, including Johnson & Johnson, Roche, and Bristol Myers Squibb. By converting lengthy multi-hour intravenous infusions into rapid subcutaneous injections administered in minutes, commercial partner therapies experienced sustained patient uptake across oncology and immunology clinics globally.
Royalty Revenue Advances 44% Driven by Broad Commercial Subcutaneous Adoption
Supported by accelerating partner product sales, Halozyme executive leadership raised its full-year 2026 financial guidance. Total revenue is currently projected to fall between $1.860 billion and $1.925 billion, reflecting annual expansion of 33 to 38 percent. Full-year royalty revenues are guided to reach between $1.235 billion and $1.255 billion, an increase of 42 to 45 percent over 2025 levels. Adjusted EBITDA is expected to reach $1.240 billion to $1.290 billion, while non-GAAP diluted EPS is projected at $8.75 to $9.05, even after absorbing approximately $60 million in new proprietary drug delivery investments.
Raising Full-Year 2026 Revenue Target to $1.925 Billion as Drug Price Impact Remains Minimal
Healthcare equity analysts noted that Halozyme's capital-light intellectual property licensing model yields exceptional cash flow conversion, with nine-month operating cash flow reaching $679.2 million. The steady addition of clinical pipeline candidates across global pharmaceutical alliances continues to compound long-term royalty visibility across multi-year patent horizons.
